Cerep and Servier Establish a new Collaboration Agreement for Drug Discovery and Lead Optimization
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Cerep announces the signature with Servier of a 3-year collaboration agreement for the discovery and optimization of new drugs. The terms of the agreement provide that Servier will identify targets of interest and will transfer to Cerep its collection of compounds.
Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.
As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.
In addition, Servier will have access to BioPrint® services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimized safety profile.
Financial terms of the agreement are undisclosed; they include a monthly payment during the 3 years of the collaboration. Thierry Jean, Chairman and CEO of Cerep, commented: "Servier is an historical partner of Cerep and we have continuously entertained excellent relationships. We are particularly happy to sign a new collaboration which illustrates the high level of confidence and respect shared by the two companies."
Emmanuel Canet, President of Research and Development of Servier, declared: "With this agreement, Servier takes a new step in its contribution to medical progress and therapeutic innovation and confirms its commitment to collaborate with innovative biotech and research companies in France."
Bernard Marchand, Research Director at Servier, added: "With its experience in the development of new pharmacological assays, its organization and expertise in compound management and screening, but also the access to its BioPrint® database and tools, Cerep is a partner of choice for our new drug discovery research programs."
Cerep will be responsible for the development and validation of the corresponding pharmacological assays and will run high throughput screenings on Servier library.
As part of this agreement, Cerep will also profile hit compounds identified during the high throughput screening campaigns as well as the drug candidates optimized for the selected target. Screening and profiling data will be made available in real time through the secured web access system Data OnLine developed by Cerep.
In addition, Servier will have access to BioPrint® services for an improved interpretation of in vitro data and for a better selection of drug candidates with less potential side effects and optimized safety profile.
Financial terms of the agreement are undisclosed; they include a monthly payment during the 3 years of the collaboration. Thierry Jean, Chairman and CEO of Cerep, commented: "Servier is an historical partner of Cerep and we have continuously entertained excellent relationships. We are particularly happy to sign a new collaboration which illustrates the high level of confidence and respect shared by the two companies."
Emmanuel Canet, President of Research and Development of Servier, declared: "With this agreement, Servier takes a new step in its contribution to medical progress and therapeutic innovation and confirms its commitment to collaborate with innovative biotech and research companies in France."
Bernard Marchand, Research Director at Servier, added: "With its experience in the development of new pharmacological assays, its organization and expertise in compound management and screening, but also the access to its BioPrint® database and tools, Cerep is a partner of choice for our new drug discovery research programs."
